Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

NCT00353678 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

1141

Enrollment

INDUSTRY

Sponsor class

Conditions

Thromboembolism

Interventions

DRUG: YM150

Sponsor

Astellas Pharma Inc

Collaborators

[object Object]